Benedetta Bodini1,2, Emilie Poirion1, Matteo Tonietto1, Charline Benoit1, Raffaele Palladino3,4, Elisabeth Maillart1,2, Erika Portera1, Marco Battaglini5, Geraldine Bera1,2, Bertrand Kuhnast6, Céline Louapre1,2, Michel Bottlaender6, Bruno Stankoff7,2. 1. Sorbonne Universités, Institut du Cerveau et de la Moelle épinière, ICM, Hôpital de la Pitié Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France. 2. Assistance Publique des Hôpitaux de Paris, France. 3. School of Public Health, Imperial College of London, London, United Kingdom. 4. University "Federico II" of Naples, Naples, Italy. 5. Department of Neurological Sciences, University of Siena, Siena, Italy; and. 6. CEA, Université Paris Sud, Université Paris-Saclay, Service Hospitalier Frédéric Joliot, Orsay, France. 7. Sorbonne Universités, Institut du Cerveau et de la Moelle épinière, ICM, Hôpital de la Pitié Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France bruno.stankoff@aphp.fr.
Abstract
Our objective was to develop a novel approach to generate individual maps of white matter (WM) innate immune cell activation using 18F-DPA-714 translocator protein PET and to explore the relationship between these maps and individual trajectories of worsening disability in patients with multiple sclerosis (MS). Methods: Patients with MS (n = 37), whose trajectories of worsening disability over the 2 y preceding study entry were calculated, and healthy controls (n = 19) underwent MRI and 18F-DPA-714 PET. A threshold for significant activation of 18F-DPA-714 binding was calculated with a voxelwise randomized permutation-based comparison between patients and controls and used to classify each WM voxel in all subjects as characterized by a significant activation of innate immune cells (DPA+) or not. Individual maps of innate immune cell activation in the WM were used to calculate the extent of activation in WM regions of interests and to classify each WM lesion as DPA-active, DPA-inactive, or unclassified. Results: Compared with the WM of healthy controls, patients with MS had a significantly higher percentage of DPA+ voxels in the normal-appearing WM (NAWM) (NAWM in patients, 24.6% ± 1.4%; WM in controls, 14.6% ± 2.0%; P < 0.001). In patients with MS, the percentage of DPA+ voxels increased significantly from the NAWM to the perilesional areas, T2 hyperintense lesions, and T1 hypointense lesions (38.1% ± 2.6%, 45.0% ± 2.6%, 51.8% ± 2.6%, respectively; P < 0.001). Among the 1,379 T2 lesions identified, 512 were defined as DPA-active and 258 as DPA-inactive. A higher number of lesions classified as DPA-active (odds ratio, 1.13; P = 0.009), a higher percentage of DPA+ voxels in the NAWM (odds ratio, 1.16; P = 0.009), and a higher percentage of DPA+ voxels in T1 spin-echo lesions (odds ratio, 1.06; P = 0.036) were significantly associated with a retrospectively more severe clinical trajectory in patients with MS. Conclusion: A more severe trajectory of disability worsening in MS is associated with innate immune cell activation inside and around WM lesions. 18F-DPA-714 PET may provide a promising biomarker to identify patients at risk of a severe clinical trajectory.
Our objective was to develop a novel approach to generate individual maps of white matter (WM) innate immune cell activation using 18F-DPA-714 translocator protein PET and to explore the relationship between these maps and individual trajectories of worsening disability in patients with multiple sclerosis (MS). Methods:Patients with MS (n = 37), whose trajectories of worsening disability over the 2 y preceding study entry were calculated, and healthy controls (n = 19) underwent MRI and 18F-DPA-714 PET. A threshold for significant activation of 18F-DPA-714 binding was calculated with a voxelwise randomized permutation-based comparison between patients and controls and used to classify each WM voxel in all subjects as characterized by a significant activation of innate immune cells (DPA+) or not. Individual maps of innate immune cell activation in the WM were used to calculate the extent of activation in WM regions of interests and to classify each WM lesion as DPA-active, DPA-inactive, or unclassified. Results: Compared with the WM of healthy controls, patients with MS had a significantly higher percentage of DPA+ voxels in the normal-appearing WM (NAWM) (NAWM in patients, 24.6% ± 1.4%; WM in controls, 14.6% ± 2.0%; P < 0.001). In patients with MS, the percentage of DPA+ voxels increased significantly from the NAWM to the perilesional areas, T2 hyperintense lesions, and T1 hypointense lesions (38.1% ± 2.6%, 45.0% ± 2.6%, 51.8% ± 2.6%, respectively; P < 0.001). Among the 1,379 T2 lesions identified, 512 were defined as DPA-active and 258 as DPA-inactive. A higher number of lesions classified as DPA-active (odds ratio, 1.13; P = 0.009), a higher percentage of DPA+ voxels in the NAWM (odds ratio, 1.16; P = 0.009), and a higher percentage of DPA+ voxels in T1 spin-echo lesions (odds ratio, 1.06; P = 0.036) were significantly associated with a retrospectively more severe clinical trajectory in patients with MS. Conclusion: A more severe trajectory of disability worsening in MS is associated with innate immune cell activation inside and around WM lesions. 18F-DPA-714 PET may provide a promising biomarker to identify patients at risk of a severe clinical trajectory.
Authors: Laura A N Peferoen; Daphne Y S Vogel; Kimberley Ummenthum; Marjolein Breur; Priscilla D A M Heijnen; Wouter H Gerritsen; Regina M B Peferoen-Baert; Paul van der Valk; Christine D Dijkstra; Sandra Amor Journal: J Neuropathol Exp Neurol Date: 2015-01 Impact factor: 3.685
Authors: Eero Rissanen; Jouni Tuisku; Johanna Rokka; Teemu Paavilainen; Riitta Parkkola; Juha O Rinne; Laura Airas Journal: J Nucl Med Date: 2014-04-07 Impact factor: 10.057
Authors: Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2005-12 Impact factor: 10.422
Authors: Marie T Fischer; Rakhi Sharma; Jamie L Lim; Lukas Haider; Josa M Frischer; Joost Drexhage; Don Mahad; Monika Bradl; Jack van Horssen; Hans Lassmann Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: David R Owen; Astrid J Yeo; Roger N Gunn; Kijoung Song; Graham Wadsworth; Andrew Lewis; Chris Rhodes; David J Pulford; Idriss Bennacef; Christine A Parker; Pamela L StJean; Lon R Cardon; Vincent E Mooser; Paul M Matthews; Eugenii A Rabiner; Justin P Rubio Journal: J Cereb Blood Flow Metab Date: 2011-10-19 Impact factor: 6.200
Authors: Milena Sales Pitombeira; Michel Koole; Kenia R Campanholo; Aline M Souza; Fábio L S Duran; Davi J Fontoura Solla; Maria F Mendes; Samira L Apóstolos Pereira; Carolina M Rimkus; Geraldo Filho Busatto; Dagoberto Callegaro; Carlos A Buchpiguel; Daniele de Paula Faria Journal: Eur J Nucl Med Mol Imaging Date: 2022-07-15 Impact factor: 10.057
Authors: William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis Journal: Lancet Neurol Date: 2020-11 Impact factor: 44.182
Authors: Robert K Doot; Anthony J Young; Ilya M Nasrallah; Reagan R Wetherill; Andrew Siderowf; Robert H Mach; Jacob G Dubroff Journal: Cells Date: 2022-09-30 Impact factor: 7.666